PIONYR Immunotherapeutics
ClosedForging a new path in immuno-oncology.
South San Francisco, United States · Founded 2015 · $355.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- pionyrtx.com
- Total Funding
- $355.0M
- Last Round
- $275.0M Corporate RoundJun 2020
- Rounds
- 4
About
Pionyr Immunotherapeutics was a South San Francisco, California-based clinical-stage biotechnology company founded in 2015. The company's myeloid tuning approach targeted suppressive myeloid cells in the tumor microenvironment using novel antibody therapeutics, offering a differentiated mechanism from checkpoint inhibitors. Pionyr raised $175 million in total funding. Gilead Sciences secured an exclusive acquisition option in 2020 but declined to exercise it. Pionyr was subsequently acquired by Ikena Oncology in August 2023.
Summary
PIONYR Immunotherapeutics is a Biotech company based in South San Francisco, United States, founded in 2015. It has raised $355.0M in total across 4 rounds, most recently a $275.0M Corporate Round round in Jun 2020. Investors include New Enterprise Associates, Gilead Sciences and SV Health Investors.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2023
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...